| Literature DB >> 10623705 |
J E Harris1, L Ryan, H C Hoover, R K Stuart, M M Oken, A B Benson, E Mansour, D G Haller, J Manola, M G Hanna.
Abstract
PURPOSE: A randomized phase III clinical trial of adjuvant active specific immunotherapy (ASI) with an autologous tumor cell-bacillus Calmette-Guérin (BCG) vaccine was conducted to determine whether surgical resection plus ASI was more beneficial than resection alone in stage II and III colon cancer patients. PATIENTS AND METHODS: Patients (n = 412) with colon cancer (297 with stage II disease, 115 with stage III disease) were randomly allocated to an observation arm or to a treatment arm in which they received three weekly intradermal vaccine injections of 10(7) irradiated autologous tumor cells beginning approximately 4 weeks after surgery. The first two weekly injections also contained 10(7) BCG organisms. Patients were observed for determination of time to recurrence and disease-free and overall survival.Entities:
Mesh:
Substances:
Year: 2000 PMID: 10623705 DOI: 10.1200/JCO.2000.18.1.148
Source DB: PubMed Journal: J Clin Oncol ISSN: 0732-183X Impact factor: 44.544